DBV Technologies Email Format

Biotechnology ResearchÎle-de-france, France201-500 Employees

DBV Technologies is a global clinical-stage biopharmaceutical company focused on developing therapies for immune-related diseases. Founded by pediatricians, it pursues epicutaneous immunotherapy delivered through its Viaskin platform to re-educate the immune system via the skin. Its work centers on addressing food allergies, a condition that affects millions, with the aim of delivering the first epicutaneous treatment for peanut allergy and exploring broader applications for inflammatory and autoimmune diseases.
Based in Châtillon, in the Île-de-France region of France, the company operates in the biotechnology research sector. In 2026, DBV Technologies engaged with the broader biotech community through industry events, including participation at the Guggenheim Securities Emerging Outlook: Biotech Summit in New York.

Sign up for free to view info

Company overview Employee directory